The low percentage of HER2 positive ovarian cancer cases may be among the reasons why routine HER2 testing is not performed, however NSCLC adenocarcinoma cases are increasingly sent for ALK testing even though the prevalence of ALK positivity is estimated to be only about 5% [4]. This evidence concerns the gene ALK and ovarian cancer.